-
1
-
-
4944249117
-
BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L et al. BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
2
-
-
79955974210
-
-
US Food and Drug Administration. Nexavar (sorafenib) prescribing information. Available at: (accessed 10 June 2010).
-
US Food and Drug Administration. Nexavar (sorafenib) prescribing information. Available at: (accessed 10 June 2010).
-
-
-
-
3
-
-
33744984843
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
-
Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2505-2512
-
-
Ratain, M.J.1
Eisen, T.2
Stadler, W.M.3
-
4
-
-
70249097380
-
Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
-
Escudier B, Eisen T, Stadler WM et al. Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-18.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3312-3318
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
5
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
6
-
-
33748325763
-
Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis
-
Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-6.
-
(2006)
Br J Cancer
, vol.95
, pp. 581-586
-
-
Eisen, T.1
Ahmad, T.2
Flaherty, K.T.3
-
7
-
-
70149124507
-
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
-
Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-5.
-
(2009)
Cancer
, vol.115
, pp. 4090-4095
-
-
Dreicer, R.1
Li, H.2
Stein, M.3
-
8
-
-
70149087258
-
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
-
Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-24.
-
(2009)
Anticancer Drugs
, vol.20
, pp. 616-624
-
-
Bianchi, G.1
Loibl, S.2
Zamagni, C.3
-
9
-
-
67149130074
-
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
-
Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-40.
-
(2009)
BJU Int
, vol.103
, pp. 1636-1640
-
-
Aragon-Ching, J.B.1
Jain, L.2
Gulley, J.L.3
-
10
-
-
50649095250
-
Phase II trial of sorafenib in advanced thyroid cancer
-
Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-19.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4714-4719
-
-
Gupta-Abramson, V.1
Troxel, A.B.2
Nellore, A.3
-
11
-
-
34548504810
-
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
-
Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3766-3773
-
-
Elser, C.1
Siu, L.L.2
Winquist, E.3
-
12
-
-
65349161533
-
A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens
-
abstract).
-
Schiller JH, Lee JW, Hanna NH et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. J Clin Oncol 2008; 26 (Suppl.): 8014 (abstract).
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL..
, pp. 8014
-
-
Schiller, J.H.1
Lee, J.W.2
Hanna, N.H.3
-
13
-
-
59949103514
-
Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase ll trial of the University of Chicago Phase ll Consortium
-
abstract).
-
Wiebe L, Kasza K, Maki RG et al. Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase ll trial of the University of Chicago Phase ll Consortium. J Clin Oncol 2008; 26 (Suppl.): 10502 (abstract).
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL..
, pp. 10502
-
-
Wiebe, L.1
Kasza, K.2
Maki, R.G.3
-
14
-
-
33748913369
-
Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma
-
abstract).
-
Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2008; 26 (Suppl.): 7002 (abstract).
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL..
, pp. 7002
-
-
Gatzemeier, U.1
Blumenschein, G.2
Fosella, F.3
-
15
-
-
62449186539
-
Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma
-
Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1280-1289
-
-
Escudier, B.1
Szczylik, C.2
Hutson, T.E.3
-
16
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
17
-
-
73749087933
-
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer
-
Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 4469-74.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4469-4474
-
-
Di Lorenzo, G.1
Cartenì, G.2
Autorino, R.3
-
18
-
-
67650293850
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
-
Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-40.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3133-3140
-
-
Maki, R.G.1
D'Adamo, D.R.2
Keohan, M.L.3
-
19
-
-
59449089100
-
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response
-
Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
-
(2009)
Cancer
, vol.115
, pp. 428-436
-
-
Yau, T.1
Chan, P.2
Ng, K.K.3
-
20
-
-
58149335533
-
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
-
Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27: 11-15.
-
(2009)
J Clin Oncol
, vol.27
, pp. 11-15
-
-
Moreno-Aspitia, A.1
Morton, R.F.2
Hillman, D.W.3
-
21
-
-
40749122148
-
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
-
Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-14.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 209-214
-
-
Dahut, W.L.1
Scripture, C.2
Posadas, E.3
-
22
-
-
36249017922
-
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
-
Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-62.
-
(2007)
Jpn J Clin Oncol
, vol.37
, pp. 755-762
-
-
Akaza, H.1
Tsukamoto, T.2
Murai, M.3
-
23
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
-
24
-
-
34648863567
-
The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy
-
abstract).
-
Knox JJ, Figlin R, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007; 25 (Suppl. 18): 5011 (abstract).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.. 18
, pp. 5011
-
-
Knox, J.J.1
Figlin, R.2
Stadler, W.M.3
-
25
-
-
37349126289
-
Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)
-
abstract).
-
D'Adamo DR, Keohan M, Schuetze S et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol 2007; 25 (Suppl. 18): 10001 (abstract).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.. 18
, pp. 10001
-
-
D'Adamo, D.R.1
Keohan, M.2
Schuetze, S.3
-
26
-
-
41349094931
-
MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumours (NET): a Phase II consortium (P2C) study
-
abstract).
-
Hobday TJ, Holen K, Picus J et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumours (NET): a Phase II consortium (P2C) study. J Clin Oncol 2007; 25 (Suppl. 18): 4004 (abstract).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.. 18
, pp. 4004
-
-
Hobday, T.J.1
Holen, K.2
Picus, J.3
-
27
-
-
38349030422
-
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
-
Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-34.
-
(2007)
Clin Exp Med
, vol.7
, pp. 127-134
-
-
Porta, C.1
Paglino, C.2
Imarisio, I.3
-
28
-
-
0034231616
-
Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: incidence, recognition and management
-
Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
-
(2000)
Am J Clin Dermatol
, vol.1
, pp. 225-234
-
-
Nagore, E.1
Insa, A.2
Sanmartin, O.3
-
29
-
-
58149345018
-
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
-
Robert C, Mateus C, Spatz A et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305.
-
(2009)
J Am Acad Dermatol
, vol.60
, pp. 299-305
-
-
Robert, C.1
Mateus, C.2
Spatz, A.3
-
30
-
-
33846924560
-
Hand-foot and stump syndrome to sorafenib
-
Lai SKT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25: 341.
-
(2007)
J Clin Oncol
, vol.25
, pp. 341
-
-
Lai, S.K.T.1
Lacouture, M.2
-
31
-
-
52949138886
-
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
-
Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-61.
-
(2008)
Ann Oncol
, vol.19
, pp. 1955-1961
-
-
Lacouture, M.E.1
Reilly, L.M.2
Gerami, P.3
-
32
-
-
34247361171
-
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
-
Tsai KY, Yang CH, Kuo TT et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24: 5786-8.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5786-5788
-
-
Tsai, K.Y.1
Yang, C.H.2
Kuo, T.T.3
-
33
-
-
0028293816
-
Expression of c-kit ligand in human keratinocytes
-
Morita E, Lee DG, Sugiyama M et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994; 286: 273-7.
-
(1994)
Arch Dermatol Res
, vol.286
, pp. 273-277
-
-
Morita, E.1
Lee, D.G.2
Sugiyama, M.3
-
34
-
-
21344462378
-
Cutaneous side-effects of kinase inhibitors and blocking antibodies
-
Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
-
(2005)
Lancet Oncol
, vol.6
, pp. 491-500
-
-
Robert, C.1
Soria, J.C.2
Spatz, A.3
-
35
-
-
71949112710
-
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
-
Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51.
-
(2009)
Br J Dermatol
, vol.161
, pp. 1045-1051
-
-
Lee, W.J.1
Lee, J.L.2
Chang, S.E.3
-
36
-
-
77949517580
-
Management of vascular endothelial growth factor and multikinase inhibitor side effects
-
Wood LS. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs 2009; 13 (Suppl.): 13-18.
-
(2009)
Clin J Oncol Nurs
, vol.13
, Issue.SUPPL..
, pp. 13-18
-
-
Wood, L.S.1
|